







08:00 Registration	
08:50 Opening plenary 1	
BLUE AUDITORIUM	<p>Welcome</p> <p><b>ANTON USSI</b> REMEDI4ALL/EATRIS Chair</p>
	<p>Welcome remarks from César Hernández</p> <p><b>CÉSAR HERNÁNDEZ</b> SPANISH MINISTRY OF HEALTH Keynote</p>
	<p>REMEDI4ALL Our aspirations and achievements so far</p> <p><b>DONALD LO</b> REMEDI4ALL/EATRIS Keynote</p>
	<p>Drug repurposing for rare diseases: the Alkaptonuria and nitisinone story</p> <p><b>NICK SIREAU</b> AKU SOCIETY Keynote</p>
	<p>Medicines Repurposing to Benefit Patients in the NHS: The Anastrozole Story</p> <p><b>ROSIE LOVETT</b> NHS ENGLAND Keynote</p>
<p>CURE ID: Using Real-World Data on Drug Repurposing to Identify Promising Treatments for Areas of Unmet Medical Need</p> <p><b>HEATHER STONE</b> U.S. FDA Keynote</p>	
10:30 Morning break	
11:00 Opening plenary 2	
BLUE AUDITORIUM	<p>Challenge of translation from the patient and scientist perspective</p> <p><b>NICK BISHOP</b> UNIVERSITY OF SHEFFIELD Keynote</p>
	<p>Challenges and solutions for off-patent drug repurposing</p> <p><b>ADRIAN VAN DEN HOVEN</b> MEDICINES FOR EUROPE Keynote</p>
	<p>Drug repurposing from innovative industry's perspective - Reflection on potential legislative changes</p> <p><b>SINI ESKOLA</b> EFPIA Keynote</p>
	<p>Stakeholder perspectives regarding efficacy: What is clinically meaningful?</p> <p><b>MARCO SCHITO</b> C-PATH Keynote</p>
	<p>What is efficacy anyway?</p> <p><b>MARCO SCHITO</b> C-PATH Chair</p> <p><b>JAMES CONNELL</b> LIFEARC Panelist</p> <p><b>LARS SCHLOTAWA</b> UNIVERSITY MEDICAL CENTRE GOETTINGEN Panelist</p> <p><b>DAN O'CONNOR</b> MHRA Panelist</p> <p><b>CÉSAR HERNÁNDEZ</b> SPANISH MINISTRY OF HEALTH Panelist</p>
12:45 Lunch break	

14:00 Pathway session 1 (running in parallel)	
GREEN AUDITORIUM CANCER PATH	<p>Cancer patients need repurposed drugs</p> <p><b>PATRICIA VANDAMME</b> ANTICANCER FUND Chair</p> <p><b>CLAUDIA FUCHS</b> EURORDIS Chair</p>
	<p>Drug repurposing for functional precision medicine Developing therapeutics for the rare cancer, fibrolamellar hepatocellular carcinoma.</p> <p><b>SANFORD SIMON</b> ROCKEFELLER UNIVERSITY Keynote</p>
	<p>Repurposing of active drugs in sarcoma: a huge need and unique opportunity to fight discrimination against rare cancers</p> <p><b>SILVIA STACCHIOTTI</b> FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI Keynote</p>
BLUE AUDITORIUM METHODOLOGIES PATH	<p>Finding hope in repurposed drugs - metformin to reduce cancer incidence in Li Fraumeni Syndrome</p> <p><b>PAN PANTZIARKA</b> GEORGE PANTZIARKA TP53 TRUST Keynote</p>
	<p>Empowering innovation: Hyloris addresses unmet patient needs through viable repurposing and reformulation</p> <p><b>BÉNÉDITH OBEN</b> HYLORIS PHARMACEUTICALS Keynote</p>
	<p>Turn of times: From opportunistic discovery to data- driven hypothesis generation in drug repurposing</p> <p><b>BRINTON SEASHORE-LUDLOW</b> SCILIFELAB Chair</p>
YELLOW AUDITORIUM RARE DISEASES PATH	<p>Accelerating drug discovery with microscopy and machine learning</p> <p><b>ANNE CARPENTER</b> BROAD INSTITUTE OF HARVARD AND MIT Keynote</p>
	<p>Drug repurposing for viral diseases</p> <p><b>DENIS KAINOV</b> NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY Keynote</p>
	<p>Target(s) and MoA deconvolution by multi- factorial /-parametric design of PISA with integrated orthogonal proteomics</p> <p><b>MASSIMILIANO GAETANI</b> SCILIFELAB Keynote</p>
GREEN AUDITORIUM CANCER PATH	<p>Need for a Standardized Translational Platform Lessons from COVID-19 Drug Repurposing</p> <p><b>PETER SJÖ</b> DNDI Keynote</p>
	<p>Drug repurposing research at NCATS</p> <p><b>MATTHEW HALL</b> NCATS Keynote</p>
	<p>Why care about repurposing for rare diseases?</p> <p><b>RICK THOMPSON</b> BEACON FOR RARE DISEASES Chair</p>
	<p>The Patient Perspective</p> <p><b>SHIRA STRONGIN</b> CURE ID Keynote</p>
	<p>Patient, caregivers and patient organisation perspective on repurposing</p> <p><b>ALAN FINGLAS</b> MSD ACTION FOUNDATION Keynote</p>
YELLOW AUDITORIUM RARE DISEASES PATH	<p>Rare disease research - challenges and opportunities</p> <p><b>HEINZ JUNGLUTH</b> KING'S COLLEGE LONDON Keynote</p>
	<p>Essential factors to interest pharma and biotech in drug repurposing</p> <p><b>DAVID BROWN</b> HEALX LTD Keynote</p>
15:30 Afternoon break	

16:00 Pathway session 2 (running in parallel)		
GREEN AUDITORIUM CANCER PATH	Selecting the strongest drug repurposing candidates to move to the clinic	 <b>PAN PANTZIARKA</b> ANTICANCER FUND Chair
		 <b>AIMO KANNT</b> FRAUNHOFER INSTITUTE FOR TRANSLATIONAL MEDICINE AND PHARMACOLOGY Chair
	Drug combination strategies for challenging childhood brain cancers	 <b>JAVAD NAZARIAN</b> UNIVERSITY CHILDREN'S HOSPITAL, ZÜRICH Keynote
	Pharmacoscopy - individualised drug repurposing? Discovery of repurposable drugs through image-based screening in patient biopsies	 <b>BEREND SNIJDER</b> ETH ZÜRICH Keynote
	Reverse Molecular Pharmacology: using existing drugs to reveal targetable vulnerabilities in refractory cancers	 <b>EDDY PASQUIER</b> CANCER RESEARCH CENTER OF MARSEILLE Keynote
	 <b>CHRISTINE COLVIS</b> NCATS Keynote	
BLUE AUDITORIUM METHODOLOGIES PATH	Mind the gap: What are the blockers and how can we smoothen the transition from discovery to clinic?	 <b>MADDALENA FRATELLI</b> IRCCS ISTITUTO DI RICERCA FARMACOLOGICHE MARIO NEGRI Chair
	Drug repurposing in the LLM era	 <b>TUDOR OPREA</b> UNM HEALTH SCIENCES CENTER Keynote
	Extracting and Leveraging Real-World Data: Solutions for US healthcare data	 <b>SMITH HEAVNER</b> CDRC Keynote
	A pragmatic approach through "FAIR" - the FAIRplus story	 <b>NICK JUTY</b> THE UNIVERSITY OF MANCHESTER Keynote
	ALK inhibitor drug repurposing through non-canonical mechanisms	 <b>UWE RIX</b> H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE Keynote
How can regulators facilitate drug repurposing?	 <b>MARJON PASMOOIJ</b> DUTCH MEDICINES EVALUATION BOARD Keynote	
YELLOW AUDITORIUM RARE DISEASES PATH	Leading a drug repurposing project	
	Challenging the status quo: patient group, clinician, and researcher-led drug repurposing	 <b>RICK THOMPSON</b> BEACON FOR RARE DISEASES Chair
		 <b>NICK SIREAU</b> AKU SOCIETY Panelist
		 <b>OSCAR DELLA PASQUA</b> UCL Panelist
		 <b>BARBARA GOODMAN</b> CURES WITHIN REACH Panelist
	 <b>PROF TIM BARRETT</b> UNIVERSITY OF BIRMINGHAM Panelist	

YELLOW AUDITORIUM RARE DISEASES PATH	
Lightning talks	
SIMPATHIC: Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular diseases by exploiting SIMilarities in clinical and molecular PATHology	 <b>PETER-BRAM'T HOEN</b> RABDOUD UNIVERSITY MEDICAL CENTER Lightning talk
Challenges in Repurposed Drug Development for Rare Diseases: A Strategic Pipeline Presentation	 <b>DANIELA SANGES</b> TELETHON INSTITUTE OF GENETICS AND MEDICINE Lightning talk
Losartan for epidermolysis bullosa - a clinical stage repurposed drug candidate	 <b>TOBIAS ZAHN</b> PHARMA CONSULTING GMBH Lightning talk
Repurposing Etidronate for Pseudoxanthoma Elasticum	 <b>VINCENT VAN DER WEL</b> ORFENIX Lightning talk
The problem of translating repurposed drugs from the lab to the patient: the need for a new policy framework	 <b>PAUL MARTIN</b> UNIVERSITY OF SHEFFIELD Lightning talk
17:30 Poster session & drinks reception	
19:00 End of day one	



SCAN TO DOWNLOAD THE DIGITAL POSTER PACK

08:30 Registration	
08:50 Pathway session 3 (running in parallel)	
GREEN AUDITORIUM CANCER PATH	<p>Trialling repurposed drugs with access to patients in mind</p> <p><b>GAUTHIER BOUCHE</b> ANTICANCER FUND Chair</p> <p><b>CHRISTINE KUBIAK</b> ECRIN Chair</p>
	<p>A dual approach to bringing repurposed drugs to patients: clinical trials and real world registries</p> <p><b>VIKAS P. SUKHATME</b> EMORY SCHOOL OF MEDICINE Keynote</p>
	<p>Repurposing in Oncology Trials</p> <p><b>RUTH LANGLEY</b> UNIVERSITY COLLEGE LONDON Keynote</p>
	<p>Drug repositioning for rare mosaic disorders: example of alpelisib for patients with PIK3CA-related disorders</p> <p><b>GUILLAUME CANAUD</b> HÔPITAL NECKER ENFANTS MALADES Keynote</p>
BLUE AUDITORIUM METHODOLOGIES PATH	<p>Repurposing drugs with access to patients in mind: a funder's perspective</p> <p><b>ALEXANDRE COSTA ALENCAR</b> THE RISING TIDE FOUNDATION FOR CLINICAL CANCER RESEARCH Keynote</p>
	<p>Reality check: Can methodological advancement unlock the promises of drug repurposing?</p> <p><b>JOHANNA HUCHTING</b> FRAUNHOFER ITMP Chair</p>
	<p>Current Research and Drug Repurposing Pathways in Long Covid</p> <p><b>HANNAH DAVIS</b> PATIENT-LED RESEARCH COLLABORATIVE Keynote</p>
	<p>Exploring the pleiotropic effects of medicines: The role of synthetic data.</p> <p><b>ANDREA BECCARI</b> DOMPÉ FARMACEUTICI SPA Keynote</p>
	<p>Enabling mechanism-based repurposing through REPO4EU platform</p> <p><b>EMRE GÜNEY DOGAN</b> STALICLA Keynote</p>
	<p>Accommodating heterogeneity in a basket trial design for drug repurposing in neurologic disorders</p> <p><b>JOANNA INTHOUT</b> RADBODUMC Keynote</p>
	<p>A new, complementary theory of pharmaceutical incentives and innovation</p> <p><b>JOHN LIDDI COAT</b> KING'S COLLEGE LONDON Keynote</p>
YELLOW AUDITORIUM RARE DISEASES PATH	<p>Roundtable discussion: Innovative methods enabling successful drug repurposingn</p> <p><b>DONALD LO</b> R4A, EATRIS Panel co-chair</p> <p><b>MATT HALL</b> NCATS Panel co-chair</p>
	<p>The evolving rare disease landscape</p>
	<p>4-Phenylbutyrate for SLC6A1-Meaningful Outcomes and Access</p> <p><b>LINDSAY RANDALL</b> ARTHUR'S QUEST Keynote</p>
	<p>Market access of a PUMA medicinal product (kigabeq®)</p> <p><b>LAURENT MARTIN</b> ORPHELIA PHARMA Keynote</p>
	<p>Repurposing for an ultra-rare disease: delivery of the TREATWOLFRAM international randomised controlled trial</p> <p><b>TIMOTHY BARRETT</b> INSTITUTE OF CANCER AND GENOMIC SCIENCES Keynote</p>
	<p>Repurposing for rare: opportunities for the rare disease community</p> <p><b>ANNELINE JONKER</b> UNIVERSITY OF TWENTE   IRDIRC Keynote</p>
<p>Repurposing – a Funder's Perspective</p> <p><b>JOANNA DAVIDGE</b> LIFEARC Keynote</p>	

11:00 Morning break		
11:30 Pathway plenary - Cancer & Rare Diseases		
BLUE AUDITORIUM	<p>Getting repurposed drugs to patients</p> <p><b>ZSUZSANNA PETYKÓ</b> SYREON RESEARCH INSTITUTE Chair</p> <p><b>DONALD LO</b> R4A, EATRIS Chair</p> <p><b>HUGH LEONARD</b> THE EHE RARE CANCER CHARITY Panelist</p> <p><b>CHRISTELLE BOUYGUES</b> EUROPEAN MEDICINES AGENCY Panelist</p> <p><b>FRANK HULSTAERT</b> KCE Panelist</p> <p><b>NIVEDITA VALENTINE</b> PHARMANOVIA Panelist</p> <p><b>JOHN LIDDI COAT</b> KING'S COLLEGE LONDON Panelist</p> <p><b>ROSIE LOVETT</b> NHS ENGLAND Panelist</p>	
	12:30 Lunch break	
	13:30 Closing plenary	
	BLUE AUDITORIUM	<p>Presentation of the winning poster from the poster session</p>
		<p>Challenges and opportunities in drug repurposing</p> <p><b>RICK THOMPSON</b> BEACON FOR RARE DISEASES Chair</p>
		<p>'Trick or treat' - learnings from the LODOCO case</p> <p><b>SACO DE VISSER</b> FAST Chair</p> <p><b>AREND MOSTERD</b> MEANDER MEDICAL CENTER Panelist</p> <p><b>HEATHER STONE</b> U.S. FDA Panelist</p> <p><b>HANS WAALS</b> TIOFARMA Panelist</p> <p><b>SIBREN VAN DEN BERG</b> AMSTERDAM UMC Panelist</p> <p><b>DONALD LO</b> R4A, EATRIS Panelist</p>
		<p>From Serendipity to Systemized Drug Repurposing: Unlocking the lifesaving potential of FDA-approved medicines</p> <p><b>GRANT MITCHELL</b> EVERY CURE Keynote</p>
<p>Closing Remarks</p> <p><b>RICK THOMPSON</b> BEACON FOR RARE DISEASES Chair</p>		
15:00 End of day two		